Tromsø, Norway, 16[th] of March 2023 - ArcticZymes Technologies ASA (OSE: AZT)
has filed a new patent application within the field of RNA based therapeutics.
The patent application covers a new nuclease enzyme composition and method-of
-use in the processing and analysis of RNA for therapeutic purposes. RNA therapy
is the treatment or prevention of diseases by using modified RNA molecules.

Developing RNA for therapeutic purposes is challenging and time consuming and
requires high-end instrumentation. The new enzyme can ease and improve the
analytical processes for therapeutic RNA for both developers and manufacturers.

There is currently no similar enzyme available on the market. ArcticZymes
Technologies has initiated client testing of a prototype, gathering performance
data and feedback prior to entering product development.

ArcticZymes Technologies ASA, CSO, Darren Ellis said: "We are excited by the new
patent application and prototype and how it can help clients accelerate their
processes. This again demonstrates the innovation capabilities at ArcticZymes
bringing forward patentable enzyme technology that can aid the development of
innovative therapies."

For more information, please contact:

ArcticZymes Technologies
CFO, Børge Sørvoll        Tel: +47 95 29 01 87
CSO, Darren Ellis         Tel: +47 47 31 50 97
                            ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

The Company is listed on the Oslo Stock Exchange since 2005 as ArcticZymes
Technologies under the [AZT] ticker. Its headquarters are based in Tromsø,
Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com.